| (V1236) |
Effect of Upstream Clopidogrel Treatment on Infarct Size and Microvascular Obstruction Assessed by CMR in Patients with STEMI Undergoing Primary PCI |
|
S. de Waha, S. Desch, I. Eitel, G. Fürnau, P. Lurz, G. C. Schuler, H. Thiele (Leipzig) |
| (V1237) |
High residual platelet reactivity after thienopyridine therapy in patients in therapeutic hypothermia after cardiac arrest – a clinically relevant problem? |
|
K. Ibrahim, M. Christoph, S. Schmeinck, K. Schmieder, S. Kolschmann, K. Steiding, C. Pflücke, S. Kindler, S. Schön, R. H. Strasser, C. Wunderlich (Dresden) |
| (V1238) |
Unerwartet hohe Aggregationsergebnisse bei Patienten nach PCI mit Ticagrelor Therapie in der Mehrfach-Elektroden-Aggregometrie |
|
F. Schmidtler, E. Hitzke, L. Nowak, A. Leber, M. Schmidt, J. Rieber, E. Hoffmann, D. H. Antoni (München) |
| (V1239) |
Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a real world myocardial infarction registry |
|
C. Olivier, C. Brandt, Q. Zhou, P. Diehl, C. Bode, M. Moser (Freiburg im Breisgau; Melbourne, AU) |
| (V1240) |
Use of prasugrel im primary percutaneous intervention in daily clinical practice. Results of the prospective ATACS registry. |
|
U. Zeymer, M. Hochadel, N. Kaul, S. Hoffmann, R. Zahn, A. K. Gitt (Ludwigshafen, Koblenz, Berlin) |
| (V1241) |
A novel RNA-aptamer direct Factor IXa-inhibitor (pegnivacogin) reduces platelet activation In vitro and residual platelet aggregation on treatment with clopidogrel in patients with ACS |
|
V. Putz, C. Vetter, S. Zelenkofske, M. Moser, R. C. Becker, C. Rusconi, C. Bode, I. Ahrens (Freiburg im Breisgau; Baskin Ridge, Durham, US) |